Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Baxter To Acquire Continuous Renal Replacement Therapy Business From Edwards Lifesciences
Baxter International Inc. (NYSE:BAX) announced today a definitive agreement with Edwards Lifesciences Corporation (NYSE:EW) under which Baxter will acquire certain assets related to Edwards" hemofiltration product line, also known as Continuous Renal Replacement Therapy (CRRT). The transaction is expected to close in the third quarter of 2009, pending regulatory approvals.
generic viagra online
Raptor Pharmaceuticals Doses First Patient In Phase 2b Clinical Trial Of DR Cysteamine For Cystinosis
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), announced that it has dosed the first patient in its Phase 2b clinical trial, conducted in collaboration with the University of California, San Diego ("UCSD"), to evaluate Raptor"s proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare genetic lysosomal storage disease. Under Raptor"s open Investigational New Drug application ("IND"), UCSD is performing the Raptor-sponsored trial at its General Clinical Research Center.
News of the day
Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control And Reduces Weight
New Phase II data presented at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
Mental Health

Heart Failure Patients With Cognitive Impairment Have Higher Mortality Risk

"There are data in the literature suggesting an increased mortality in patients with chronic heart failure who are additionally suffering from cognitive decline", said Dr. Clotilde Balucani (Perugia, Italy) at the current meeting of the European Neurological Society (ENS). This major meeting in European neurology is gathering more than 2,900 experts from all over the world in Milan. Dr. Balucani and her colleagues are presenting a study funded by a research grant of the ENS. The French-Italian research team analyzed data from three studies involving a total of 896 patients suffering from cardiac insufficiency, half of whom were cognitively impaired. Heart failure is associated with a high mortality rate even among patients not cognitively impaired: 17,9 % (after 6 months), 25,6 % (after 12 months) und 68,2 % (after 60 months). The mortality rate was even much higher in heart failure patients with cognitive impairment, with rates of 35,6 %, 40 % and 96.3 %. "Data are yet too scarce to identify whether this is just the result of an increased morbidity in patients with cognitive impairment or if there is a direct causal relationship due to undertreatment or poor compliance," adds Dr. Balucani who would like to see more research in this area. Abstract: ENS abstract O119: Balucani et al, Does cognitive impairment influence outcome in congestive heart failure? A systematic review. European Neurological Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009